Respiratory Syncytial Virus (RSV) — Brookshire's

Fact checked by Robert Carlson, MD

Oct 8

3 min read

RSV Vaccine Candidate Produced 10-20 Fold Increase in Virus-Killing Antibodies

RSVpreF vaccine candidate has the potential to prevent Respiratory Syncytial Virus disease in infants by immunizing pregnant women

pregnant woman protecting her baby

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Oct 3

4 min read

$51 Million Dollars Raised For RSV Vaccine Development

Icosavax IVX-121 RSV vaccine candidate incorporates a stabilized prefusion F antigen

older woman healthy

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Sep 5

3 min read

FDA Breakthrough Therapy Designation Granted for Respiratory Syncytial Virus Vaccine

Janssen Ad26.preF based RSV vaccine candidate launched a phase 2b clinical study

older man contemplating

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Aug 15

3 min read

ResVax Demonstrated Significant Vaccine Efficacy Against Infant Pneumonia Early in Life

Novavax ResVax is an aluminum adjuvanted respiratory syncytial virus fusion protein recombinant nanoparticle vaccine

happy little girl with dad

Respiratory Syncytial Virus (RSV)

Fact checked by Robert Carlson, MD

Aug 1

6 min read

Longhorn & NIH Leading Innovative RSV Vaccine Study

DS-Cav1 vaccine candidate elicited large increases in RSV-neutralizing antibodies sustained for several months

grandpa holding a sleeping grandchild

Respiratory Syncytial Virus (RSV)